What does this research mean for the field?

Semaglutide and tirzepatide yield similar clinical outcomes in patients with obesity and heart failure with preserved ejection fraction (HFpEF). Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Open Access

Semaglutide vs tirzepatide in patients with obesity and HFpEF: a report from a global federated research network

Puntos clave

No difference in clinical outcomes was observed between semaglutide and tirzepatide.
The analysis focused on patients diagnosed with both obesity and HFpEF.

PICO estructurado

Does semaglutide improve clinical outcomes compared to tirzepatide in patients with obesity and HFpEF?

Población

Patients with obesity and HFpEF from a global federated research network

Intervención

Semaglutide

Comparador

Tirzepatide

Resultado

Clinical outcomes

Real-world data suggests comparable clinical outcomes between semaglutide and tirzepatide in patients with obesity and HFpEF.

Resumen

In this real-world analysis, no difference was observed between semaglutide and tirzepatide in terms of clinical outcomes among patients with obesity and HFpEF.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo